ImmunID, an immune molecular diagnostics company, announced today that the ethic committee and regulatory bodies have granted authorizations to start its PREDICT-ID Melanoma study to assess the predictive value of immune profiles for response to Ipilimumab®, an immunomodulatory agent approved in more than 40 countries.
ImmunID strategic goal is to set the global immune Molecular Diagnostic (iMDx) standard. As part of its strategy, ImmunID is focusing on cancers and particularly on metastatic melanoma, a cancer with high unmet needs. After decades of disappointing results with chemotherapy or targeted therapy, recent clinical successes observed with immunotherapy in melanoma (Ipilimumab, an anti-CTLA-4 antibody, Nivolumab and Pembrolizumab, two anti-PD-1 antibodies, as well as other immune checkpoint inhibitors) confirm the relevance of using the body’s own immune system against the tumor. Unfortunately, only a small subset of patients achieves benefit from these immunotherapies, which at the same time, can cause serious adverse events. So far no marker predicting response or toxicity has been found for these therapies, which expose a high proportion of patients to unnecessary safety risk, potentially without benefit.